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Abstract
Background: Beta thalassemia is the most frequent genetic disorder of haemoglobin synthesis in Pakistan.
Recurrent transfusions lead to iron-overload manifested by increased serum Ferritin levels, for which chelation
therapy is required.
Findings: The study was conducted in the Pediatric Emergency unit of Civil Hospital Karachi after ethical approval
by the Institutional Review Board of Dow University of Health Sciences. Seventy nine cases of beta thalassemia
major were included after a written consent. The care takers were interviewed for the socio-demographic variables
and the use of Desferrioxamine therapy, after which a blood sample was drawn to assess the serum Ferritin level.
SPSS 15.0 was employed for data entry and analysis.
Of the seventy-nine patients included in the study, 46 (58.2%) were males while 33 (41.8%) were females. The
mean age was 10.8 (± 4.5) years with the dominant age group (46.2%) being 10 to 14 years. In 62 (78.8%) cases,
the care taker education was below the tenth grade. The mean serum Ferritin level in our study were 4236.5 ng/
ml and showed a directly proportional relationship with age. Desferrioxamine was used by patients in 46 (58.2%)
cases with monthly house hold income significant factor to the use of therapy.
Conclusions: The mean serum Ferritin levels are approximately ten times higher than the normal recommended
levels for normal individuals, with two-fifths of the patients not receiving iron chelation therapy at all. Use of iron
chelation therapy and titrating the dose according to the need can significantly lower the iron load reducing the
risk of iron-overload related complications leading to a better quality of life and improving survival in Pakistani beta
thalassemia major patients.
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Background
Beta thalassemia ranks first amongst the genetic disor-
ders associated with haemoglobin synthesis in terms of
prevalence and it is the result of an inherited defect in
the synthesis of the beta chain of the adult haemoglobin.
Consequently the erythropoiesis is defective and anemia
is produced [1]. Considering the 5 to 7% carrier rate in
Pakistan, the number of carriers is expected to approach
10 million [2]. This grades thalassemia as one of the
most common inherited disorders in Pakistan [3]. Due
to lack of appropriate documentation, precise data per-
taining to the incidence and prevalence of the disease
are lacking. However, different studies statistically esti-
mate that the number of thalassemia major patients
born each year is in the order of 4000 to 9000 [4,5].
Due to repeated blood transfusions, all thalassemic
patients require Iron Chelation Therapy (ICT) in order
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any medium, provided the original work is properly cited.to reduce the increased iron load that if not eliminated
properly can result in life threatening complications,
including severe cardiac toxicity in the second decade of
life, producing a significant decrease in the total life
expectancy of these patients [6]. However, the practice
of repeated parenteral ICT therapy imposes various eco-
nomic burdens in those who cannot afford such a ther-
apy. Oral chelators such as Deferasirox are much more
expensive than the traditional ICT’s which makes access
difficult for the majority of socio-economically under-
privileged patients [7]. Desferoxamine (DFE), a parent-
eral drug used widely as ICT has been employed in the
treatment of beta thalassemia for nearly four decades
and has shown to be effective in reducing the hepatic
and extra-hepatic adverse affects, particularly myocardial
toxicity [8]. However, despite the protracted method of
8- to 10- hours of infusion at least five times a week,
the patients suffering from beta thalassemia are often
not able to achieve the desired threshold of Ferritin
levels in their blood [9]. This study also highlighted the
dismal situation of ICT having a negative impact on
health related quality of life (HRQOL), and that in most
of the cases compliance with ICT being suboptimal, sig-
nifying non-satisfactory provision of chelation therapy
with respect to economic, clinical and quality of life
related outcome.
T h ea i mo ft h ep r e s e n ts t u d yi st oa s s e s st h es o c i o -
demographic factors, serum Ferritin levels and adher-
ence to iron chelation therapy in multi-transfused Tha-
lassemia major patients. The series is composed mainly
of Thalassemics children and young patients.
Methodology
The present study is a continuation of the work on Tha-
lassemia major patients and is carried out on the same
patients in which the sero-prevalence of viral hepatitis
and HIV was determined, published in the Tropical Dr.
Journal [10]. However, the objectives are entirely differ-
ent from the one published.
Study Design
This is a descriptive cross-sectional study, conducted
from July to September 2009 at Karachi, Pakistan’sl a r -
gest city both in terms of area and inhabitants.
Setting
This study was conducted at Civil Hospital Karachi,
one of the largest government tertiary care hospitals of
Karachi. The hospital has a Paediatric Emergency Unit
(PEU) specialized for the treatment of children pre-
senting with acute medical problems. Patients with
transfusion dependent Thalassemia (Thalassemia
major) also present to the PEU for the routine follow
up and transfusions. The fee structure of the hospital
is such that patients with lower socioeconomic strata
of the city and those referred from other centres are
treated.
Participants
Diagnosed cases of Thalassemia major that had under-
gone at least ten transfusions were included after
obtaining a written consent from their care takers.
Those who did not give consent or had lesser number
of transfusions were excluded from the study.
Study
The sampling technique was non-probability purposive
sampling. The care takers of the Thalassemia major
patients providing consent were interviewed by the stu-
dents of Dow Medical College (DMC) through a well
structured questionnaire prepared after literature search
and modified in terms of questionnaire clarity. The first
section comprised of Socio- Demographic variables.
These included age, gender, area of residency, status of
house (whether owned or at rent), monthly house-hold
income and education of the parents. The second part
was pertaining to history of vaccination for Hepatitis B
and blood group. At the completion of interview a
blood sample was obtained by venepuncture from the
patient for serological analysis of serum Ferritin levels.
Ethical Approval
The ethical approval for the study was obtained from
the Ethical Review Board (ERB) of the Dow University
of Health Sciences (DUHS).
Results
A total of 79 patients were enrolled in the study dura-
tion. The mean age was 10.8 ± 4.5 years. As shown in
Table 1, 46 (58.2%) were males where as the rest i.e. 33
(41.8%) were females. Half of the patients were between
ages 9 and 15 years.
Blood group “O” was found to be the predominant.
The results highlight the education status of the patients
showing that 78.8% of the care takers of the patients
had education less than the Matric (39.4% stating that
they “never went to school”, and an equal number
responding that they left the school during the primary
education). Most of the patients belonged to a poor
socio-economic background reflected from the monthly
h o u s eh o l di n c o m ew i t ha l lt h ec a r et a k e r sh a v i n g
income below 20,000 Pakistani Rupees PKR (Approxi-
mately 245 US dollars) per month. The preponderance
(36.4%) lies between 5000-10,000 PKR (61 US dollars-
122 US dollars) per month. Approximately three fourths
(75.8%) stated that they owned a house. The vaccination
history revealed that less than half (45.5%) care takers
stated that they vaccinated their children for Hepatitis B
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out the procedure or not.
The mean serum Ferritin levels were found to be
4236.5 (± 2378.3) ng/ml. The values in males were simi-
lar (4075.2 ± 2440.7) ng/ml compared to females (4461 ±
2306.6) ng/ml. The figure was less than 1000 ng/ml in
just 2 cases, whereas the values were between two to
three thousand ng/ml in 19 cases. Figure 1 displays the
serum Ferritin ranges and the number of patients who
fall within a specified range. 11 cases had serum Ferritin
values exceeding 7000 ng/ml. The values increased pro-
gressively with age above 9 years as suggested in Figure 2.
Desferrioxamine therapy was used by three fifth of the
patients. As expected, serum Ferritin values were much
lower (3319.6 ± 1925.8) ng/ml in the group who
received the therapy compared to those who did not use
the medication (5514.8 ± 2383.0) ng/ml. Monthly house
hold income was associated with use of Desferrioxamine
therapy, with just one third of patients below income of
3000 Rupees per month taking the medication com-
pared to over two thirds above that income.
Discussion
Iron overload is an unavoidable complication suffered by
thalassemia major patients as a consequence of excessive
number of blood transfusions. It is so common that it
has been referred to a “second disease” during treatment
of first [11]. Serum Ferritin is an easy and in-expensive
indirect measurement of iron burden, however, a single
measure may not provide reliable indication of iron
levels. The new non-invasive methods of measuring iron
storage in the body such as MRI or SQUID have greater
sensitivity, but they have limited use in developing
countries such as Pakistan because of cost and complex-
ity. As excessive iron can lead to organ complications,
chelation therapy is employed to lower its levels.
Borgna-Pignatti et al reported that a lower Ferritin con-
centration predicted longer survival, and reduced risk of
various complications [12]. Many studies concluded that
cirrhosis of liver is associated with increase in serum
Ferritin level [13-16].
Patients with lower socio-economic strata visit the
government tertiary care hos p i t a l sa sd e p i c t e di no u r
Table 1 Socio-demographic data of Thalassemia patients
and their care takers:
Variables Numbers Percentage
Gender Male 46 58.2
Female 33 41.8
In years
Age Under 5 13 16.3
5 to 9 18 23.2
10-14 37 46.5
15-above 11 14.0
A 17 21.6
Blood groups B 21 26.4
AB 2 2.6
O 39 49.4
Il-literate 31 39.4
Education of the care taker Primary 31 39.4
Matric 12 15.2
Graduate 5 6.1
Socioeconomics Less than 3000 26 33.3
(monthly house-hold
income)
3000-5000 19 24.2
5000-10,000 29 36.4
10,000-20,000 5 6.1
Status of house Own 60 75.8
On rent 19 24.2
Vaccination for Hep B Done 36 45.5
Not done 33 42.4
Don’t
remember
10 12.1
Figure 1 Serum Ferritin levels (expressed in ng/ml) and
frequency of patients in the specified range.
Figure 2 Relationship between ages (in years) and serum
Ferritin Levels (expressed in ng/ml).
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income below 20,000 rupees per month. Considering
the average 500 mg vial price of desferrioxamine to be
150-180 rupees (Approximately 5000 rupees per
month), it’s exceedingly difficult for the care takers to
cope with the therapy. These prices do not include infu-
sion devices, the cost of which is covered by the hospital
through governmental funding. Table 2 depicts the
effect of gender and monthly household income on the
use of Desferrioxamine therapy.
When not provided with desferrioxamine therapy the
patients suffer grave consequences of iron over load, the
spectrum of which lies from generalized weakness,
weight loss, joint pain, abdominal pain to critical illness
such as cirrhosis, hepatoma, diabetes, cardiomyopathy,
arthritis, arthropathy, hypopituitarism with hypogonad-
ism and death[17]. The organ most sensitive to chronic
iron overload is heart. Chronic iron over load in liver
increases chances of cirrhosis and hepatic carcinoma,
hepatoma. The death occurs mostly due to liver disease,
hepatocellular carcinoma, diabetes or cardiomyopathy
[18]. However, T2 weighted Magnetic Resonance Ima-
ging (MRI) studies show that Desferrioxamine is not as
cardio-protective as the oral chelator deferiprone as oral
d e f e r i p r o n ei sm o r ee f f e c t i v et h a nd e s f e r r i o x a m i n ei n
removal of myocardial iron [19]. Furthermore, Desfer-
rioxamine therapy is associated with adverse effects and
demands associated with administration regimen render-
ing the compliance sub-optimal. A combination regimen
of Desferrioxamine with Deferiprone is shown to be the
most rapid way of reducing iron-overload in both liver
and heart.
The mean serum Ferritin level in our study was
4236.5 ng/ml, which is markedly higher when compared
to normal serum Ferritin levels in children in which the
mean serum Ferritin level is considered to be in range
of 12-122 ng/ml [20]. The values in our study are higher
compared with similar regional and international stu-
dies. A study conducted in Islamabad, the federal capital
of our country showed the mean serum Ferritin level in
patients of beta thalassemia was 3390 ng/ml [21]. Cun-
n i n g h a me ta li n2 0 0 4r e p o r t e dm e a ns e r u mF e r r i t i n
levels in beta thalassemia patients of North America to
be 1696 ng/ml [22]. The difference is largely attributable
to the difference in the standards of healthcare between
the 2 regions. For instance, the dosage was not adjusted
with weight in our group of patients, which could con-
tribute to high Ferritin levels. However, Choudhry VP et
al in India reported mean serum Ferritin levels to be
6723 ng/ml [23], even higher than in our study.
Age and chelation therapy are significantly linked with
Ferritin levels in our study. This is depicted in the graph
(Figure 2) below, which outlines that there is a directly
proportional relationship between age inyears and the
serum Ferritin levels. Approximately four-fifths of the
patients in our study had serum Ferritin values exceed-
ing 2000 ng/ml, which is almost ten times higher than
the upper limit of normal. As expected, serum Ferritin
values were much lower (3319.6 ± 1925.8) in the group
w h or e c e i v e dt h et h e r a p yc o m p a r e dt ot h o s ew h od i d
not use the medication (5514.8 ± 2383.0). Monthly
house hold income was associated with use of Desfer-
rioxamine therapy, with just one third of patients below
income of 3000 Rupees per month taking the medica-
tion compared to over two thirds above that income.
Interestingly, female gender was associated with
increased use of Desferrioxamine therapy.
The importance of chelation therapy can be appre-
ciated from the fact that levels of Ferritin are inversely
linked to the survival in Thalassemia major patients. A
study reported that the 15 year cardiac disease free sur-
vival in patients on iron chelation therapy with Ferritin
levels below 2500 ng/ml was 91% compared to under
20% with levels in excess of this value [24].
Table 2 Effect of Gender and House Hold Income on
Desferrioxamine Use
Variable Total Number Percentage
Gender
Male 46
On DFE 24 52.2
Without DFE 22 47.8
Females 33
On DFE 22 66.6
Without DFE 11 33.3
House hold income (Rs.) Less than 3000 20 25.3
On DFE 8 40.0
Without DFE 12 60.0
3000-5000 35 44.3
On DFE 23 65.7
Without DFE 12 34.3
5000-10000 22 27.8
On DFE 14 63.6
Without DFE 8 36.4
10000-20000 2 2.5
On DFE 1 50.0
Without DFE 1 50.0
DFE = Desferrioxamine
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The height and weight (and consequently the body mass
index) of the patients was not obtained. The dose and
frequency of Desferrioxamine infusions is not ascer-
tained and is also a limitation.
Conclusions
The problems of poverty, low education level and inade-
quate provision of health care are the main stumbling
blocks in effective treatment of thalassemic patients of
iron over load, the complications of which are the main
cause of morbidity and mortality in thalassemia major.
Recommendations
Use of Depefirone, routine measurements of serum Fer-
ritin levels, adherence to guidelines, awareness amongst
the public for prevention of the disease and antenatal
diagnosis are some of the methods which can decrease
the sufferings of not only the patients, but also of their
families.
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